412 related articles for article (PubMed ID: 30090122)
1. Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy.
VavalĂ T; Novello S
Ther Adv Med Oncol; 2018; 10():1758835918789364. PubMed ID: 30090122
[TBL] [Abstract][Full Text] [Related]
2. Chinese perspectives on clinical efficacy and safety of alectinib in patients with
Yu H; Sun S; Hu X; Xia J; Wang J; Chen H
Onco Targets Ther; 2019; 12():6481-6495. PubMed ID: 31616158
[TBL] [Abstract][Full Text] [Related]
3. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
Santarpia M; Altavilla G; Rosell R
Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
[TBL] [Abstract][Full Text] [Related]
4. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
Yoshida T; Hida T; Yatabe Y
Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
[TBL] [Abstract][Full Text] [Related]
5. Treating ALK-positive non-small cell lung cancer.
Ziogas DC; Tsiara A; Tsironis G; Lykka M; Liontos M; Bamias A; Dimopoulos MA
Ann Transl Med; 2018 Apr; 6(8):141. PubMed ID: 29862230
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.
Muller IB; de Langen AJ; Giovannetti E; Peters GJ
Onco Targets Ther; 2017; 10():4535-4541. PubMed ID: 28979145
[TBL] [Abstract][Full Text] [Related]
7. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
Crvenkova S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
9. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer.
Wang WQ; Xu T; Zhang JJ; Wang Y; Wang Y; Zhang W; Zhu JG
J Thorac Dis; 2023 Apr; 15(4):1935-1947. PubMed ID: 37197536
[TBL] [Abstract][Full Text] [Related]
11. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
Karachaliou N; Fernandez Bruno M; Bracht JWP; Rosell R
Onco Targets Ther; 2019; 12():4567-4575. PubMed ID: 31354290
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.
VavalĂ T; Mariniello A; Novello S
Transl Cancer Res; 2019 Jan; 8(Suppl 1):S48-S54. PubMed ID: 35117063
[TBL] [Abstract][Full Text] [Related]
14. A case of
Makuuchi Y; Hayashi H; Haratani K; Tanizaki J; Tanaka K; Takeda M; Sakai K; Shimizu S; Ito A; Nishio K; Nakagawa K
Oncotarget; 2018 May; 9(33):23315-23319. PubMed ID: 29796191
[TBL] [Abstract][Full Text] [Related]
15. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial therapy is a safe and durable treatment option in
Jang C; Sabari J
Transl Lung Cancer Res; 2023 Dec; 12(12):2558-2564. PubMed ID: 38205199
[TBL] [Abstract][Full Text] [Related]
17. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
Zhu V; Ou SH
Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in
Zhu VW; Nagasaka M; Kubota T; Raval K; Robinette N; Armas O; Al-Holou W; Ou SI
Lung Cancer (Auckl); 2020; 11():13-18. PubMed ID: 32021525
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
20. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]